Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDSVAX VaxGen.

Andreas Billich1

  • 1Novartis Research Institute, PO Box 80, Brunner Strasse 59, A-1235, Wien, Austria. andreas.billich@pharma.novartis.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 27, 2004
PubMed
Summary

VaxGen is developing AIDSVAX, an investigational bivalent vaccine for Human Immunodeficiency Virus (HIV) prevention. This vaccine, in phase III trials, aims to generate antibodies against prevalent HIV subtypes in different global regions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Based and Property-Driven Optimization of <i>N</i>-Aryl Imidazoles toward Potent and Selective Oral RORγt Inhibitors.

Journal of medicinal chemistry·2019
Same author

Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model.

Journal of medicinal chemistry·2018
Same author

Interferon regulatory factor 5 and nuclear factor kappa-B exhibit cooperating but also divergent roles in the regulation of pro-inflammatory cytokines important for the development of TH1 and TH17 responses.

The FEBS journal·2018
Same author

Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.

PloS one·2017
Same author

Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.

Scientific reports·2017
Same author

Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations.

JCI insight·2017

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Human Immunodeficiency Virus (HIV) remains a significant global health challenge.
  • Developing an effective preventive vaccine is a critical research priority.

Purpose of the Study:

  • To evaluate the efficacy of AIDSVAX, a bivalent recombinant gp120 vaccine, in preventing HIV infection.
  • To assess the immune response generated by different vaccine formulations against specific HIV subtypes.

Main Methods:

  • Phase III clinical trials are underway for two vaccine versions: AIDSVAX B/E and AIDSVAX B/B.
  • The trials involve participants in Thailand, the US, and Europe.
  • The vaccine is designed to stimulate antibody production against specific HIV subtypes.

Main Results:

  • AIDSVAX B/E targets HIV subtypes prevalent in South Asia, Southeast Asia, and the Pacific Rim.
  • AIDSVAX B/B targets HIV subtypes found in the Americas, Europe, and Australia.
  • Both vaccine versions are designed to induce a specific antibody response.

Conclusions:

  • AIDSVAX represents a potential strategy for HIV prevention through targeted antibody induction.
  • Ongoing phase III trials will determine the vaccine's effectiveness in diverse populations and against regional HIV strains.

Related Experiment Videos